LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 2 | G06 | 72 | hr | 1476 | 1054 | 3694 | 0.2853 | -0.1906 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 3 | G06 | 72 | hr | 1476 | 878 | 3694 | 0.2377 | -0.2700 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 1 | P18 | 72 | hr | 1476 | 3012 | 3694 | 0.8154 | 0.6924 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 2 | P18 | 72 | hr | 1476 | 2770 | 3694 | 0.7499 | 0.5833 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 3 | P18 | 72 | hr | 1476 | 2747 | 3694 | 0.7436 | 0.5729 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 1 | A12 | 72 | hr | 1476 | 2264 | 3694 | 0.6129 | 0.3551 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 2 | A12 | 72 | hr | 1476 | 2265 | 3694 | 0.6132 | 0.3555 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 3 | A12 | 72 | hr | 1476 | 2134 | 3694 | 0.5777 | 0.2964 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1476 | 4520 | 3694 | 1.2236 | 1.3725 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1476 | 4113 | 3694 | 1.1134 | 1.1889 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1476 | 3934 | 3694 | 1.0650 | 1.1082 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 1 | A24 | 72 | hr | 1476 | 2972 | 3694 | 0.8045 | 0.6744 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 2 | A24 | 72 | hr | 1476 | 2839 | 3694 | 0.7685 | 0.6144 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 1476 | 2801 | 3694 | 0.7583 | 0.5972 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 1 | P12 | 72 | hr | 1476 | 3173 | 3694 | 0.8590 | 0.7650 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 2 | P12 | 72 | hr | 1476 | 2998 | 3694 | 0.8116 | 0.6861 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 3 | P12 | 72 | hr | 1476 | 2771 | 3694 | 0.7501 | 0.5837 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 1 | D06 | 72 | hr | 1476 | 3682 | 3694 | 0.9967 | 0.9946 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 2 | D06 | 72 | hr | 1476 | 3762 | 3694 | 1.0184 | 1.0306 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 3 | D06 | 72 | hr | 1476 | 3747 | 3694 | 1.0143 | 1.0239 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 1 | I06 | 72 | hr | 1476 | 3730 | 3694 | 1.0097 | 1.0162 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 2 | I06 | 72 | hr | 1476 | 4128 | 3694 | 1.1175 | 1.1957 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 3 | I06 | 72 | hr | 1476 | 3329 | 3694 | 0.9012 | 0.8354 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 1476 | 3162 | 3694 | 0.8560 | 0.7601 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 1476 | 2719 | 3694 | 0.7361 | 0.5603 |